Home | About PR | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |   Login 
Pharmacognosy Magazine
Search Article 
  
Advanced search 
 


 
 Table of Contents 
ORIGINAL ARTICLE
Year : 2016  |  Volume : 8  |  Issue : 5  |  Page : 50-55  

Kolaviron, biflavonoid complex from the seed of Garcinia kola attenuated angiotensin II- and lypopolysaccharide-induced vascular smooth muscle cell proliferation and nitric oxide production


1 Department of Veterinary Physiology, Biochemistry and Pharmacology, Faculty of Veterinary Medicine, University of Ibadan, Ibadan, Nigeria
2 Department of Environmental and Interdisciplinary Sciences, College of Science, Engineering, and Technology; Vascular Biology Unit, Center for Cardiovascular Diseases, College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX 77004, USA

Date of Web Publication14-Mar-2016

Correspondence Address:
Momoh Audu Yakubu
Department of Environmental and Interdisciplinary Sciences, COSET, Texas Southern University, 3100 Cleburne Avenue, Houston, TX 77004
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0974-8490.178647

Rights and Permissions
   Abstract 

Introduction: Kolaviron (KV), a biflavonoid extract from Garcinia kola seeds has been reported to possess anti-inflammatory, anti-oxidant, hepato-protective, cardio-protective, nephro-protective and other arrays of chemopreventive capabilities but the mechanism of action is still not completely understood. Materials and Methods: In this study, we investigated the anti-proliferative, anti-inflammatory and anti-oxidative potential of KV in cultured Vascular Smooth Muscle Cells (VSMCs). Effects of KV (25-100 μg/mL) on VSMC proliferation alone or following treatments with mitogen and proinflammatory agents Angiotensin II (Ag II, 10-6 M) and lipopolysaccharide (LPS, 100 μg/mL) and effects on NO production were determined. Cellular proliferations were determined by MTT assay, nitric oxide (NO) level was determined by Griess assay. KV dose-and time dependently attenuated VSMC growth. Results: Treatment of VSMCs with Ag II and LPS significantly enhanced proliferation of the cell which was significantly attenuated by the treatment with KV. Treatment of VSMC with LPS significantly increased nitric oxide (NO) level in the media which was attenuated by KV. These results demonstrated anti-proliferative anti-inflammatory properties of KV as it clearly inhibited cellular proliferation induced by mitogens as well as LPS-induced inflammatory processes. Conclusion: Therefore, KV may mitigate cardiovascular conditions that involve cell proliferation, free radical generation and inflammatory processes such as hypertension, diabetes and stroke. However, the molecular mechanism of action of KV needs to be investigated.

Keywords: Angiotensin II, cardiovascular diseases, cell proliferation, kolaviron, lipopolysaccharide, nitric oxide, vascular smooth muscle cells


How to cite this article:
Oyagbemi AA, Omobowale TO, Adedapo AA, Yakubu MA. Kolaviron, biflavonoid complex from the seed of Garcinia kola attenuated angiotensin II- and lypopolysaccharide-induced vascular smooth muscle cell proliferation and nitric oxide production. Phcog Res 2016;8, Suppl S1:50-5

How to cite this URL:
Oyagbemi AA, Omobowale TO, Adedapo AA, Yakubu MA. Kolaviron, biflavonoid complex from the seed of Garcinia kola attenuated angiotensin II- and lypopolysaccharide-induced vascular smooth muscle cell proliferation and nitric oxide production. Phcog Res [serial online] 2016 [cited 2020 May 26];8, Suppl S1:50-5. Available from: http://www.phcogres.com/text.asp?2016/8/5/50/178647

Summary

  • Angiotensin-induced cell proliferation
  • Kolaviron mitigates angiotensin-induced cell proliferation
  • Kolaviron ameliorates nitric oxide production
  • Kolaviron offers antioxidant activity.


Abbreviations Used: VSMCs: Vascular Smooth Muscle Cells, Ag II: Angiotensin II, KV: Kolaviron, LPS: lypopolysaccharide, NO: Nitric Oxide, DMEM: Dulbecco's modified Eagle's medium, MTT: (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide), DMSO: Dimethylsulfoxide, GB1: Garcinia kola biflavonoid-1, GB2: Garcinia kola biflavonoid-2, ROS: Reactive oxygen species, ET-1: Endothelin-1, NF-κB: Nuclear factor-kappa beta, COX-2: Cyclooxygenase-2


   Introduction Top


Kolaviron (KV), a biflavonoid from Garcinia kola seed extract is reportedly known as the most active phytochemical present in Garcinia kola seed.[1] KV has been extensively reported for its various pharmacological and medicinal properties including radio-protective, protection against reproductive toxicant, hypoglycaemic, hypolipidemic, and gastro protective.[2],[3],[4] The chemopreventive potentials and medicinal properties of Garcinia kola and Kolaviron have also been documented elsewhere.[5],[6],[7],[8]

Cardiovascular disease condition involves various processes that lead to the release of mitogenic agents which can act under favourable conditions to generate free radicals as well as activate and propagate inflammatory processes manifesting in various cardiovascular diseases such as hypertension, stroke, diabetes etc.[9],[10] Despite research advances, care/management of these conditions is still difficult to achieve. Majority of population suffering from cardiovascular diseases live in developing countries where accesses to modern medications are limited. Often, this population resort to use of herbal products to manage their health conditions. However, the mechanism/mode of action of these plants derived remedies is lacking. GK is one of the plant derived remedies that is used for various disease conditions.[11] In the present study, we have evaluated the effect of Kolaviron, a biflavonoid fraction from GK on mitogen-induced proliferation of VSMCs. Ag II and LPS are known mitogens, proinflammatory, pro-oxidants, proliferative and they possible act through activations of cascade of signalling pathways initially separately, converging later to activate common pathways that may regulate cellular functions possibly via transcription factors.[9],[11],[12],[13],[14] As cardiovascular pathologies involve these myriads of pathways, Ang II and LPS activated pathways will be a good model for testing the possible actions of KV in cardiovascular dysfunction in vitro.


   Materials and Methods Top


Chemicals and reagents

Reagents used in this study were Dulbecco's modified Eagle's medium (DMEM), MTT, Anti-biotic and anti-mycotic consisting of 100 U/mL penicillin G sodium, 100 mg/mL streptomycin sulphate, 2.5 mg/mL amphotericin B and Trypsin-EDTA. They were purchased from Sigma-Aldrich, St Louis, MO. Matrigel (BD Biosciences, Franklin Lakes, NJ. All other chemicals and reagents were of pure analytical grade.

Extraction of Garcinia kola and isolation of Kolaviron

Kolaviron was extracted from the seeds of Garcinia Kola according to the method of Iwu with slight modification.[1] The seeds were sliced, air-dried and powdered. The powdered seeds were defatted by extraction using n-hexane in a Soxhlet extractor apparatus for 24 hours. The defatted dried marc was repacked and extracted with methanol. Kolaviron was fractionated from concentrated methanolic extract using chloroform to give a golden brown solid which consists of Garcinia biflavanones – GB1, GB2 and kolaflavanone.


   Methods Top


Vascular smooth muscle cell culture

VSMC was a gift from Dr. Ranganna of the RCMI Core Lab at TSU, Houston. The cells were cultured and maintained as previously described.[15] Briefly, VSMC were culture in a culture flask T75 and maintained at 37O C in a humidified 5% CO2 incubator in a 20% FBS conditioned DMEM plus anti-biotic consisting of 100 U/mL penicillin G sodium, 100 mg/mL streptomycin sulphate, and 2.5 mg/mL amphotericin B until confluent. Confluent cells were trypsinized and plated in a 96-well plates at a population of 7,000 cell per well for proliferation assays. For determination of treatment on NO production, cells were cultured in a 12-well culture plates.

Effects of KV on LPS VSMC proliferation

To determine effects of KV on cellular proliferation, 24 hours following cell seeding in 96 well plates, cells were treated with KV (25-100 µg/mL) and cell growth determined at 24, 48, 72, or 96 hours following treatments.



Effects of KV on Ag II- and LPS-induced VSMC proliferation

To determine the effects of KV on mitogen-induced VSMC growth, 24 hours following plating of VSMC in 96 wells, cells were exposed to Ag II (10-6 M) or LPS (100 µg/mL) in the presence or absence of KV (25-100 µg/mL). The treated plates were further incubated for 24, 48, 72, or 96 hours before effects of treatments on proliferation determined.

Effects of KV on LPS-induced NO production

To determine effects of LPS-induced NO production, VSMC were seeded on matrigel coated 24 well plates and incubated until 75-80% confluent before treatment with LPS (100 µg/mL) in the presence or absence of KV (25-100 µ g/mL) for 4 hours. At the end of the incubation, media was removed and stored in -80o C until needed for NO determination.

MTT assay

VSMC proliferation was determined using MTT assay. MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay is based on the ability of life cell actively metabolizing to reduce MTT to purple formazan crystal in the mitochondria of living cells. The degree of purple formazan crystals formation is proportionate to the life cells. Following 24, 48, 72 or 96 hours incubation of VSMC with vasoactive agents –KV, Ag II, LPS, alone or in combination; 20 µl of 5 mg/mL MTT was added to the 96 well plates and incubated for 3 hours. At the end of the incubation, the purple formazan crystals were dissolved with the addition of 150 µL DMSO and absorbance determined at 540 nm wavelength using Bio-Tek Plate Reader (Model ELX 800, BioTek Instruments, Winooski, Vermont, USA). The proliferation assay was conducted in triplicates, experiments repeated at least 4 times and expressed as mean of % change in VSMC growth.

Determination of nitric oxide (NO)

NO level in the media was determined using the Griess assay as describe previously.[16] Briefly, assay samples were mixed with an equal volume of the Griess reagent [0.1% N (1-naphthyl) ethylenediamine dihydrochloride and 1% sulfanilamide in 3% H3 PO4] and incubated to yield a chromophore. Using a Bio-Tek Instruments plate reader (model EL808UV; Uniooski, VT), absorbance at 540 nm was measured and nitrite concentration was determined using a nitrite standard curve. The efficiency was at least 95%. The assay was conducted in triplicate, experiments repeated at least 4 times and results were expressed as nM/mL.

Statistical analysis

Data are presented as mean ± S.E.M of n = 4-6. Differences between groups were assessed using one-way ANOVA followed by Turkey comparison tests. A value of P < 0.05 was considered significant.


   Results Top


Effects of KV VSMC proliferation

[Figure 1] shows effects of treatment of VSMC with KV (25, 50, 100 µg/ml) for 24 hours. VSMC growth was reduced by 14, 6, and 15.4% following treatments with 25, 50, 100 µg/ml KV respectively. This reduction in cell growth was significantly (P< 0.05) different from the control [Figure 1], n = 4].
Figure 1: Effects of 24 h incubation of vascular smooth muscle cell with kolaviron (25–100 μg/mL) on cell growth

Click here to view


Effects of KV on Ag II- and LPS-induced VSMC proliferation

[Figure 2]a,[Figure 2]b,[Figure 2]c,[Figure 2]d shows effects of KV (25, 50, 100 µg/ml) treatment on Ag II (10-6 M)-induced VSMC proliferation at 24, 48, 72 and 96 hours. The 24 hours incubation of VSMC with Ag II (10-6 M) significantly (P< 0.006) increased VSMC proliferation by 173.3% compared to the control (100%). The increase in cell proliferation induced by Ag II was significantly (P< 0.05) attenuated by KV, reducing cell growth from 173.3% to 84.8 ± 5.0, 94.2 ± 1.8, and 84.6 ± 3.3% of the control level for KV (25, 50, 100 µg/ml) respectively [Figure 2]a, n = 4].
Figure 2: (a.-d) Effects of 24, 48, 72, or 96 h incubation of vascular smooth muscle cell with kolaviron (25.100 μg/mL) on Ag II (1 μM).-induced vascular smooth muscle cell proliferation

Click here to view


48 hours treatment of VSMC with Ag II significantly increased cell growth from 114 ± 5.9% (control) to 187.7 ± 37.9% (Ag II) (P< 0.05). This increased VSMC growth-induced by Ag II was prevented by treatments with KV (25, 50, 100 µg/ml) reducing cellular growth to 81.9 ± 9%, 73.7 ± 1.2%, 76.3 ± 3.5% of the control, respectively [Figure 2]b, n = 4].

Also, 72 hours treatment of VSMC with Ag II significantly (P< 0.05) increased VSMC growth from 121.0 ± 6.6% (control) to 162.8 ± 9.2% (Ag II). This increased VSMC proliferation induced by Ag II was significantly attenuated by treatments with KV (50 and 100 µg/mL) reducing cellular growth from 162.8 ± 9.2% (Ag II) to 78.5 ± 7.5% (KV 50 µg/mL) and 79.8 ± 7.7% (KV 100 µg/mL) respectively but not KV 25 µg/mL (149.5 ± 10.0%) when compared to Ag II (162.8 ± 9.2%) and control (121.0 ± 6.6%) [Figure 2]c, n = 4].

Similarly, 96 hours treatment of VSMC with Ag II significantly (P< 0.05) increased VSMC growth from 121.3 ± 6.6% (control) to 162.8 ± 33.6% (Ag II), this increased VSMC proliferation induced by Ag II was significantly attenuated by treatments with KV (50 and 100 µg/mL) reducing the growth from 168.0 ± 33.6% (Ag II) to 75.0 ± 12.6% (KV 50 µg/mL) and 79.8 ± 7.7% (KV 100 µg/mL) but not the lowest concentration KV 25 µg/mL with 169.7 ± 3.3% growth when compared to Ag II (168.0 ± 33.6%) and control (121.0 ± 6.6%) [Figure 2]d, n = 4].

Effects of KV on LPS-induced VSMC proliferation

[Figure 3]show effects of KV (25, 50, 100 µg/ml) treatment on LPS (100 µg/ml)-induced VSMC proliferation. 24 Hours incubation of VSMC with LPS resulted in significant (P< 0.05) growth of the cell to 262.7 ± 19.0% from the control (100%). The LPS induced growth was significantly (P< 0.05) reduced by the KV treatments to 91.7 ± 1.7% (KV 25 mg/mL), 102.3 ± 1.2% (KV 50 mg/mL), 90.8 ± 5.7% (KV 100 µg/mL) [Figure 3], n = 4].
Figure 3: Effects of 24 h incubation of vascular smooth muscle cell with kolaviron (25.100 μg/mL) on lypopolysaccharide (100 μg/mL).-induced vascular smooth muscle cell proliferation

Click here to view


Effects of KV on LPS-induced NO production

[Figure 4] shows effects of LPS-induced NO production. 4 Hours incubation of VSMC with LPS 100 µg/mL resulted in significant increase in NO. NO levels in the media were significantly (P< 0.05) increased from 33.0 ± 0.3 nM/mL in the control to 36.4 ± 0.4 nM/mL in LPS treatment. LPS-induced increases in NO production was significantly attenuated by KV reducing the NO levels from 36.4 ± 0.4 nM/mL (LPS) to 32.4 ± 0.2, 31.2 ± 1.0, 31.4 ± 0.3 nM/mL for KV 25, 50, 100 µg/mL respectively [Figure 4], n = 4]. The KV-induced attenuation of LPS-induced increases in NO levels brought the NO levels to a level comparable to that observed in the control.
Figure 4: Effects of 4 h incubation of vascular smooth muscle cell with kolaviron (25–100 μg/mL) on lypopolysaccharide (100 μg/mL)induced nitric oxide production

Click here to view



   Discussion Top


In the present study, we found that: (1) Treatment of VSMC with KV resulted in reduced VSMC growth, (2) KV attenuated Ag II-induced VSMC proliferation in a concentration and time-dependent manner, (3) 24 hours LPS treatment increased VSMC proliferation and NO production and were attenuated by KV treatment. Thus, these results demonstrated that KV possesses anti-mitogenic agents'-induced proliferation of smooth muscle cells as well as NO production via LPS mediated activation of inflammatory processes. Our findings suggest that KV possibly mediate its effects by regulating molecular signalling pathways that regulates diverse cellular functions.

Despite advances in knowledge and therapeutic drug development, cardiovascular diseases still remain a huge burden to individual and society. The processes that contribute to the initiation and maintenance of cardiovascular diseases become a target for therapeutic intervention. Cardiovascular pathologies are characterised by vascular cell proliferation, inflammation, and/or increased oxidative stress. Inflammation contributes critically to all stages of atherogenesis and cardiovascular remodelling.[17],[18] Metabolic disorders such as dyslipidemia promote activation of circulating monocytes, endothelial cells and adhesion of these cell types leading to accumulation of macrophages.[13],[17],[18] Activation of macrophages can lead to the production of proinflammatory cytokines, NO, mitogens, and reactive oxygen species.[17],[18] Cellular oxidative stress as well as other vasoactive agents can activate neighbouring cells including endothelial cells and further promotes monocyte recruitment. In addition, these processes can lead to production of mitogenic agents (Ag II, ET-1 etc.) and further propagating artherogensis. Such an uncontrolled amplification mechanism represents combined proliferative, inflammatory and oxidative stress aspects of atherosclerosis and cardiovascular disease pathologies. Numerous studies have been designed to investigate the involvement of inflammation, proliferation, and oxidative stress in cardiovascular diseases with the aim to developing agents that can prevent the development of atherosclerosis and its complications have resulted in unsatisfactory results.[13],[19] This probably could be due to the multi-factorial nature of the pathogenesis of cardiovascular diseases; hence, single remedy focused on alleviating one of these factors will result in unsatisfactory outcomes. Therefore, the target should be the development or identification of possible therapeutic agents that possess a wide range of actions against this plethora of factors and possibly mitigating against activation of common mechanistic pathways. In the present study, we have evaluated the anti-proliferative and anti-inflammatory effects of KV in cultured VSMC. We found that KV attenuated VSMC growth and sequential cell proliferation induced by Ag II and LPS as well as LPS-induced increased NO production which could mediate inflammatory processes.

It is generally accepted that Ang II and LPS as well as other mitogens such as ET-1 could activate cellular processes involved in the production of growth factors, cytokines, chemokines, and adhesion molecules, which are involved in cell growth/apoptosis, fibrosis, and inflammation.[2],[3],[4] Arterial wall production of Ang II is important in the normal regulation of arterial tone as well as its involvement in the pathogenesis of atherosclerosis. Ang II regulates many processes implicated in vascular pathophysiology, including cell growth/apoptosis of vascular cells, migration of vascular smooth muscle cells, inflammatory responses, and extracellular matrix (ECM) remodelling.[2],[3],[4] As a result of its important role in the regulation and pathogenesis of cardiovascular diseases, drugs that block Ang II actions, such as ACE inhibitors or Ang II receptor antagonists, are currently employed in the treatment of hypertension, heart failure, atherosclerosis, and other cardiovascular diseases.[2],[3],[4] Despite the widespread use of Ang II agents in clinical practice, its' mechanism (s) of action is not completely defined by which of the multiple pathways Ang II exerts its effects in the vasculature. Similarly, LPS exert its action through series of interference with vascular signalling pathways involving activation of different kinases culminating in the systemic dysfunctions observed.[2],[3],[4],[20],[21] However, we have shown in the present studies that KV possesses both anti-proliferative and anti-inflammatory properties in addition to its well known anti-oxidant effects as Ang II and LPS are pro-oxidants. The role of oxidative stress in the pathogenesis of vascular diseases is well recognized. Ang II and LPS stimulates the production of reactive oxygen species (ROS) via induction of vascular NADH oxidase mediated by gp91phox of NADPH oxidase and other subunits are mainly responsible for stimulated vascular oxidative stress and smooth muscle cells growth in vivo.[20],[21],[22] Furthermore, LPS is known to modulate pathological conditions through activation of ROS, cellular proliferation and inflammatory processes mediated by excessive production of NO. In the present study, we have shown that KV treatment prevents mitogen induced VSMC proliferation and attenuated LPS-induced generation of NO and by extension, reduction cellular stress. These actions of KV indicate that it can be useful in conditions that involve cellular proliferation, enhanced oxidative stress, and proinflammatory processes. According to our present findings, LPS-induced nitric oxide production was quenched by KV, clearly demonstrating the anti-oxidant and anti-inflammatory properties of KV.

These plethoric actions of KV observed could not be possibly linked to actions on a single pathway mediated via activation of proliferative, inflammatory, oxidative processes etc. The actions of KV observed can be attributed to inhibition of a converging single pathway that all of these signalling processes recruit to mediate these actions – a transcription factor probably. Nuclear factor-kB (NF-kB) consists of a family of transcription factors that play critical roles in inflammation, immunity, cell proliferation, differentiation, and survival. Evidences suggesting the potential role of NF-κB as a mediator of proliferative and inflammatory processes are ripped. Increases in NF-κB activity in rat's vessels has been reported following systemic infusion of Ang II and LPS administration.[20],[21],[22],[23],[24],[25] Ang II and LPS activates NF-κB in several cell types, including vascular smooth muscle, endothelial, renal, macrophages, and mononuclear cells in mediating oxidative, inflammatory, and proliferative processes.[19],[20],[21],[22],[23],[24] Although, Ang II acts through binding to two main specific receptors, AT1 and AT2, both receptors share a common molecular pathway, the activation of NF-κB.[25] LPS has been suggested to activate NF-κB in regulating proinflammatory cytokines, NO, COX-2 etc., via series of kinase activation in pathophysiology of systemic shock.[25] There are possibilities that Ang II and LPS mediated vascular dysfunctions involves activation of proliferative and inflammatory responses via redox mechanisms and NF-κB pathways. Given the large number of signals that activate NF-κB, the list of target genes controlled by NF-kB; targeting NF-kB will be a viable opportunity for prevention and treatment of cardiovascular pathology. From our present results, KV-induced attenuation of LPS and Ang II-induced proliferation and NO production possibly involves inhibition of NF-kB activation. Consistent with this possibility, is the observed ability of KV treatment to significantly reduce activation and expression of NF-kB in a cancer cell line (unpublished observation). Thus, the actions of KV observed in this study may well be mediated via inhibition of NF-kB activation but further studies are warranted to understand the molecular mechanism involve in KV-induced anti-proliferative and -inflammatory with possible role of NF-kB.


   Conclusion Top


Taken together, these results showed that KV inhibited cell proliferation and prevented the generation reactive oxygen species (ROS) and nitric oxide production mediated by LPS activation of inducible nitric oxide synthase (iNOS). In conclusion, KV possesses possible anti-oxidant, anti-proliferative and anti-inflammatory properties which would be useful in alleviating cardiovascular disease conditions and further studies are warranted to investigate the mechanism involved in the KV actions.

Acknowledgments

Carnegie African Diaspora Fellowship Program (Carnegie ADF) sponsored by The Carnegie Corporation of New York (CCNY) and administered by the Institute of International Education (IIE). We also acknowledge the support by the National Heart, Lung, and Blood Institute (Grants HL03674 and HL070669) and by the use of Research infrastructure support provided by grants G12RR003045 and CO6RR012537 awarded by the National Center for Research Resources, National Institutes of Health (NIH). The G12 program is now a part of the National Institute on Minority Health and Health Disparities (NIMHD) and the C06 program is in the Office of Research Infrastructure Programs in the Office of the Director, NIH.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
   References Top

1.
Iwu MM. Handbook of African Medicinal Plants. 1st ed. Boca Raton Florida, USA: CRC Press; 1993.  Back to cited text no. 1
    
2.
Farombi EO, Abarikwu SO, Adedara IA, Oyeyemi MO. Curcumin and kolaviron ameliorate di-n-butylphthalate-induced testicular damage in rats. Basic Clin Pharmacol Toxicol 2007;100:43-8.  Back to cited text no. 2
    
3.
Adaramoye OA, Nwaneri VO, Anyanwu KC, Farombi EO, Emerole GO. Possible anti-atherogenic effect of kolaviron (a Garcinia kola seed extract) in hypercholesterolaemic rats. Clin Exp Pharmacol Physiol 2005;32:40-6.  Back to cited text no. 3
    
4.
Adaramoye OA, Adeyemi EO. Hypoglycaemic and hypolipidaemic effects of fractions from kolaviron, a biflavonoid complex from Garcinia kola in streptozotocin-induced diabetes mellitus rats. J Pharm Pharmacol 2006;58:121-8.  Back to cited text no. 4
    
5.
Farombi EO, Tahnteng JG, Agboola AO, Nwankwo JO, Emerole GO. Chemoprevention of 2-acetylaminofluorene-induced hepatotoxicity and lipid peroxidation in rats by kolaviron – A Garcinia kola seed extract. Food Chem Toxicol 2000;38:535-41.  Back to cited text no. 5
    
6.
Farombi EO, Møller P, Dragsted LO. Ex-vivo andin vitroprotective effects of kolaviron against oxygen-derived radical-induced DNA damage and oxidative stress in human lymphocytes and rat liver cells. Cell Biol Toxicol 2004;20:71-82.  Back to cited text no. 6
    
7.
Farombi EO, Adepoju BF, Ola-Davies OE, Emerole GO. Chemoprevention of aflatoxin B1-induced genotoxicity and hepatic oxidative damage in rats by kolaviron, a natural bioflavonoid of Garcinia kola seeds. Eur J Cancer Prev 2005;14:207-14.  Back to cited text no. 7
    
8.
Brown DI, Griendling KK. Regulation of signal transduction by reactive oxygen species in the cardiovascular system. Circ Res 2015;116:531-49.  Back to cited text no. 8
    
9.
Nguyen Dinh Cat A, Montezano AC, Burger D, Touyz RM. Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxid Redox Signal 2013;19:1110-20.  Back to cited text no. 9
    
10.
Touyz RM, Berry C. Recent advances in angiotensin II signaling. Braz J Med Biol Res 2002;35:1001-15.  Back to cited text no. 10
    
11.
Carocho M, Ferreira IC. The role of phenolic compounds in the fight against cancer – A review. Anticancer Agents Med Chem 2013;13:1236-58.  Back to cited text no. 11
    
12.
Lassègue B, San Martín A, Griendling KK. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res 2012;110:1364-90.  Back to cited text no. 12
    
13.
Montezano AC, Dulak-Lis M, Tsiropoulou S, Harvey A, Briones AM, Touyz RM. Oxidative stress and human hypertension: Vascular mechanisms, biomarkers, and novel therapies. Can J Cardiol 2015;31:631-41.  Back to cited text no. 13
    
14.
Brasier AR. The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res 2010;86:211-8.  Back to cited text no. 14
    
15.
Yakubu MA, Nsaif RH, Oyekan AO. Regulation of cerebrovascular endothelial peroxisome proliferator activator receptor alpha expression and nitric oxide production by clofibrate. Bratisl Lek Listy 2010;111:258-64.  Back to cited text no. 15
    
16.
Yakubu MA, Nsaif RH, Oyekan AO. Peroxisome proliferator-activated receptora activation-mediated regulation of endothelin-1 production via nitric oxide and protein kinase C signaling pathways in piglet cerebral microvascular endothelial cell culture. J Pharmacol Exp Ther 2007;320:774-81.  Back to cited text no. 16
    
17.
Aikawa M, Manabe I, Chester A, Aikawa E. Cardiovascular inflammation. Int J Inflam 2012;2012:904608.  Back to cited text no. 17
    
18.
Linton MF, Fazio S. Macrophages, inflammation, and atherosclerosis. Int J Obes Relat Metab Disord 2003;27 Suppl 3:S35-40.  Back to cited text no. 18
    
19.
Ruiz-Ortega M, Lorenzo O, Rupérez M, Esteban V, Suzuki Y, Mezzano S, et al. Role of the renin-angiotensin system in vascular diseases: Expanding the field. Hypertension 2001;38:1382-7.  Back to cited text no. 19
    
20.
Shin JS, Park SJ, Ryu S, Kang HB, Kim TW, Choi JH, et al. Potent anti-inflammatory effect of a novel furan-2,5-dione derivative, BPD, mediated by dual suppression of COX-2 activity and LPS-induced inflammatory gene expression via NF-κB inactivation. Br J Pharmacol 2012;165:1926-40.  Back to cited text no. 20
    
21.
Hatziieremia S, Gray AI, Ferro VA, Paul A, Plevin R. The effects of cardamonin on lipopolysaccharide-induced inflammatory protein production and MAP kinase and NFkappaB signalling pathways in monocytes/macrophages. Br J Pharmacol 2006;149:188-98.  Back to cited text no. 21
    
22.
Lassègue B, Sorescu D, Szöcs K, Yin Q, Akers M, Zhang Y, et al. Novel gp91(phox) homologues in vascular smooth muscle cells: Nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 2001;88:888-94.  Back to cited text no. 22
    
23.
Wang Y, Wang GZ, Rabinovitch PS, Tabas I. Macrophage mitochondrial oxidative stress promotes atherosclerosis and nuclear factor-κB-mediated inflammation in macrophages. Circ Res 2014;114:421-33.  Back to cited text no. 23
    
24.
Chuang KH, Peng YC, Chien HY, Lu ML, Du HI, Wu YL. Attenuation of LPS-induced lung inflammation by glucosamine in rats. Am J Respir Cell Mol Biol 2013;49:1110-9.  Back to cited text no. 24
    
25.
Ruiz-Ortega M, Lorenzo O, Ruperez M, König S, Wittig B, Egido J. Angiotensin II activates nuclear transcription factor kappa β (NF-κB) through AT1 and AT2 receptors in cultured vascular smooth muscle cells. Molecular mechanisms. Circ Res 2000;86:1266-72.  Back to cited text no. 25
    

 
   Authors Top

Dr. Ademola Adetokunbo Oyagbemi, Department of Veterinary Physiology, Biochemistry and Pharmacology, Faculty of Veterinary Medicine, University of Ibadan, Nigeria. E-mail: ademola.oyagbemi778@gmail.com, Phone: +2348033639776, Fax: 028103043.
Dr. Temidayo Olutayo Omobowale, Department of Veterinary Medicine, Faculty of Veterinary Medicine, University of Ibadan, Nigeria. E-mail: bukitayo_omobowale@yahoo.com, Phone: +2348056144373, Fax: 028103043.
Dr. Adeolu Alex Adedapo, Department of Veterinary Physiology, Biochemistry and Pharmacology, Faculty of Veterinary Medicine, University of Ibadan, Nigeria. E-mail: adedapo2a@gmail.com, Phone: +2348162746222, Fax: 028103043.
Dr. Momoh Audu Yakubu, Department of Environmental and Interdisciplinary Sciences, COSET, Texas Southern University, 3100 Cleburne Avenue, Houston, TX 77004. E-mail: yakubu_ma@tsu.edu, Telephone: 713-313-4231; Fax: 713-313-4342.


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4]


This article has been cited by
1 The inhibitory effect of Isoliquiritigenin on the proliferation of human arterial smooth muscle cell
Tianbao Chen,Shaoxiong Deng,Rong Lin
BMC Pharmacology and Toxicology. 2017; 18(1)
[Pubmed] | [DOI]
2 Lipopolysaccharide induced vascular smooth muscle cells proliferation: A new potential therapeutic target for proliferative vascular diseases
Dehua Jiang,Yu Yang,Dongye Li
Cell Proliferation. 2017; : e12332
[Pubmed] | [DOI]



 

Top
  
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
    Materials and Me...
   Methods
   Results
   Discussion
   Conclusion
    References
    Authors
    Article Figures

 Article Access Statistics
    Viewed2264    
    Printed39    
    Emailed0    
    PDF Downloaded37    
    Comments [Add]    
    Cited by others 2    

Recommend this journal